Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

@article{Slamon1987HumanBC,
  title={Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.},
  author={Dennis J Slamon and Gary M. Clark and S. G. Wong and Wendy J. Levin and Axel Ullrich and William L. McGuire},
  journal={Science},
  year={1987},
  volume={235 4785},
  pages={
          177-82
        }
}
The HER-2/neu oncogene is a member of the erbB-like oncogene family, and is related to, but distinct from, the epidermal growth factor receptor. This gene has been shown to be amplified in human breast cancer cell lines. In the current study, alterations of the gene in 189 primary human breast cancers were investigated. HER-2/neu was found to be amplified from 2- to greater than 20-fold in 30% of the tumors. Correlation of gene amplification with several disease parameters was evaluated… Expand

Paper Mentions

Interventional Clinical Trial
This is a prospective, phase IIa, multicenter, randomized, open-label study comparing a pre-surgical combination of trastuzumab and pertuzumab with concurrent weekly paclitaxel… Expand
ConditionsBreast Neoplasms
InterventionDiagnostic Test, Drug, Procedure
Interventional Clinical Trial
This phase II trial studies the incidence and severity of diarrhea in patients with stage II-IIIC HER2 Positive breast cancer treated with trastuzumab and neratinib. Trastuzumab is a… Expand
ConditionsBreast Adenocarcinoma, HER2-positive Breast Cancer, Stage IIA Breast Cancer AJCC v6 and v7, (+6 more)
InterventionBiological, Drug
Interventional Clinical Trial
Breast cancer is the most common malignant tumor in women. EC-TH is one of the standard chemotherapy regimens for HER-2 positive early breast cancer(EBC). Earlier use of trastuzumab… Expand
ConditionsBreast Cancer, Neoadjuvant Chemotherapy
InterventionDrug
HER-2/neu oncogene protein and prognosis in breast cancer.
TLDR
Multivariate analyses in patients with node-negative breast cancer showed that the HER-2/neu protein is a significant independent predictor of both the disease-free and the overall survival in node-positive breast cancer, even when other prognostic factors are considered. Expand
The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.
TLDR
The review will briefly present preliminary data concerning the use of antibody-based therapies directed against the HER-2/neu protein and their potential to become a new modality for breast cancer treatment. Expand
Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group.
TLDR
It is concluded that HER-2/neu amplification is an independent predictor of shorter disease-free survival (DFS) duration in both node-negative and node-positive patients. Expand
Her-2/neu amplification and breast cancer survival: results from the Shanghai breast cancer study.
TLDR
A negative prognostic role for Her-2/neu in breast cancer survival among a Chinese population is supported, irrespective of whether FISH or CISH is used to detect amplification of the Her- 2/NEu gene. Expand
The significance of oncogene amplification in primary breast cancer
TLDR
The method used in this study allows oncogene amplification to be studied in conjunction with hormone receptor determination and thus may be of value in large clinical trials to determine the significance of oncogenes abnormalities in breast cancer. Expand
The HER‐2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy
TLDR
Preliminary data concerning the use of antibody‐based therapies directed against the HER‐2/neu protein and their potential to become a new modality for breast cancer treatment are presented. Expand
The role of HER-2 in Breast Cancer.
TLDR
Although there is no specific predictor for individual anti-cancer agents, HER-2 seems to be the most promising predictor, especially for anthracycline, although the long-term outcome is still unknown. Expand
Her-2/neu and breast cancer.
TLDR
A comprehensive review of all aspects of Her-2/neu in breast cancer, including biology, prognostic and predictive value, targeted Herceptin therapy, and the laboratory testing is provided. Expand
Overexpression of the oncogene c-erbB-2 (HER2/neu) in ovarian cancer: a new prognostic factor.
  • H. Meden, W. Kuhn
  • Medicine
  • European journal of obstetrics, gynecology, and reproductive biology
  • 1997
TLDR
The overexpression of c-erbB-2 in ovarian cancer can-be detected by immunohistochemistry staining for the protein p185 and characterizes a group with unfavorable tumor biology and a significantly worse prognosis. Expand
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.
TLDR
The concept that the HER-2/neu gene may be involved in the pathogenesis of some human cancers, including breast and ovarian cancer, is supported. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 34 REFERENCES
Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas.
TLDR
The frequency with which the c-myc gene is altered and its correlation with age suggest that it may play a role in the development of breast carcinomas. Expand
Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage.
TLDR
N-myc amplification is highly correlated with advanced stages of disease (P less than 0.001) and with the ability to grow in vitro as an established cell line, both of which are associated with a poor prognosis. Expand
Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas.
TLDR
The results suggest that genomic amplification of N-myc may have a key role in determining the aggressiveness of neuroblastomas. Expand
Progesterone receptors as a prognostic factor in stage II breast cancer.
TLDR
Examining both receptors along with other risk factors in 189 patients receiving adjuvant therapy for Stage II breast cancer suggests that determination of the progesterone-receptor concentration is of equal or greater value than determination of that of estrogen receptors. Expand
Gene amplification of c-myc and N-myc in small cell carcinoma of the lung.
TLDR
The data suggest that gene amplification is an important step in neoplastic growth in a subset of patients with small cell carcinoma of the lung and that this genetic event occurs relatively early (before metastasis) in this subset. Expand
Amplification of a novel v-erbB-related gene in a human mammary carcinoma.
TLDR
A new member of the tyrosine kinase proto-oncogene family has been identified on the basis of its amplification in a human mammary carcinoma. Expand
Human N-myc gene contributes to neoplastic transformation of mammalian cells in culture
TLDR
It is shown that enhanced expression of N-myc subsequent to co-transfections of an N- myc expression vector and the mutant c-Ha-ras-1(EJ) (from the human bladder carcinoma cell line EJ) is a factor in tumorigenic conversion of secondary rat embryo cells. Expand
A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma.
TLDR
Southern blot analysis showed close similarity of the restriction patterns of the rat c-erbB-2 gene and the rat neu oncogene, suggesting possible involvement of c- Derbyshire-related DNA clones in human cancer. Expand
Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour
TLDR
It is shown here that a DNA domain detectable by partial homology to the myc oncogene is amplified up to 140-fold in cell lines derived from different human neuroblastomas and in a neuroblastoma tumour, but not in other tumour cells showing cytological evidence for gene amplification. Expand
The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen
TLDR
A series of rat neuro/glioblastomas all contain the same transforming gene (neu) which induces synthesis of a tumour antigen of relative molecular mass (Mr) 185,000 (p185), which is serologically related to the epidermal growth factor (EGF) receptor. Expand
...
1
2
3
4
...